Amicogen Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
238
- Stock Symbol
-
092040
- Investments
-
10
- Share Price
-
$0.76
- (As of Friday Closing)
Amicogen General Information
Description
Amicogen Inc is an industrial biotechnology company operating in Korea. It is engaged in the development, production, and distribution of enzymes, bio-new materials, and healthcare food. The company's product portfolio includes special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP), and protein A chromatography resins.
Contact Information
Website
www.amicogen.comCorporate Office
- 14-10, Worasan-ro 950beon-gil
- Munsan-eup
- Jinju-si, Gyeongsangnam-do 52840
- South Korea
Corporate Office
- 14-10, Worasan-ro 950beon-gil
- Munsan-eup
- Jinju-si, Gyeongsangnam-do 52840
- South Korea
Amicogen Stock Performance
As of 13-Nov-2026, Amicogen’s stock price is $0.76. Its current market cap is $53.5M with 70.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.76 | $0.75 | $0.58 - $2.19 | $53.5M | 70.5M | 448K | -$0.24 |
Amicogen Financials Summary
As of 30-Jun-2026, Amicogen has a trailing 12-month revenue of $32.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 103,536 | 130,356 | 274,375 | 464,932 |
| Revenue | 32,169 | 29,499 | 127,235 | 122,302 |
| EBITDA | (1,965) | (8,952) | (19,699) | 666 |
| Net Income | (13,294) | (21,052) | (38,691) | (17,812) |
| Total Assets | 127,784 | 161,015 | 199,751 | 362,462 |
| Total Debt | 38,037 | 65,381 | 81,449 | 116,084 |
Amicogen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Amicogen Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amicogen Patents
Amicogen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026230824-A1 | Affinity chromatography ligand comprising z domain variant of protein a and immunoglobulin purification method using same | Pending | 29-Apr-2025 | ||
| WO-2026212444-A1 | Variants of recombinant human hyaluronidase and uses thereof | Pending | 03-Apr-2025 | ||
| WO-2026155301-A1 | Z domain variant of protein a with increased immunoglobulin elution rate, and use thereof | Pending | 15-Jan-2025 | ||
| WO-2026147265-A1 | Medium composition for culturing animal cells comprising d-chiro inositol or derivative thereof | Pending | 03-Jan-2025 | ||
| JP-2024063774-A | Deacetoxy cephalosporin c-producing bacterial strain for 7-adca production with high concentration and high purity, and production method using the same | Active | 26-Oct-2022 | C12N15/80 |
Amicogen Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amicogen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Amicogen Investments & Acquisitions (10)
Amicogen’s most recent deal was a Secondary Transaction - Private with Beyond Cell. The deal was made on 15-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Beyond Cell | 15-Jul-2024 | Secondary Transaction - Private | Discovery Tools (Healthcare) | ||
| Beyond Cell | 15-Apr-2023 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Joint Venture (Navico / Amicogen) | 02-Dec-2021 | Joint Venture | Other Commercial Services | ||
| Bifido | 21-Oct-2021 | Secondary Transaction - Private | Biotechnology | ||
| Beyond Cell | 01-Aug-2020 | Joint Venture | Discovery Tools (Healthcare) |
Amicogen ESG
Risk Overview
Risk Rating
Updated September, 30, 2025
26.35 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
Amicogen Exits (3)
Amicogen’s most recent exit was on 21-Oct-2021 from Bifido. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Bifido | 21-Oct-2021 | Completed |
|
||
| Bio-Works Technologies | 18-May-2017 | Completed |
|
||
| Skinmed | 01-Jul-2015 | Later Stage VC | Completed |
|
Amicogen Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Beyond Cell | Incheon, South Korea | 2020 | |
| Amicogen (China) Biopharm | Jining, China | 2007 |
Amicogen FAQs
-
When was Amicogen founded?
Amicogen was founded in 2000.
-
Where is Amicogen headquartered?
Amicogen is headquartered in Jinju-si, South Korea.
-
What is the size of Amicogen?
Amicogen has 238 total employees.
-
What industry is Amicogen in?
Amicogen’s primary industry is Biotechnology.
-
Is Amicogen a private or public company?
Amicogen is a Public company.
-
What is Amicogen’s stock symbol?
The ticker symbol for Amicogen is 092040.
-
What is the current stock price of Amicogen?
As of 13-Nov-2026 the stock price of Amicogen is $0.76.
-
What is the current market cap of Amicogen?
The current market capitalization of Amicogen is $53.5M.
-
What is Amicogen’s current revenue?
The trailing twelve month revenue for Amicogen is $32.2M.
-
What is Amicogen’s annual earnings per share (EPS)?
Amicogen’s EPS for 12 months was -$0.24.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
